Mon, October 7, 2024
AUS Edition NZ Edition UK Edition CA Edition USA Edition FRA Edition GER Edition ESP Edition ITA Edition NLD Edition
PRT Edition SWE Edition GRC Edition IND Edition POL Edition BRA Edition ZAF Edition RUS Edition CHN Edition UAE Edition
Kalkine Media ASX Share Market News & Research
Kalkine Media ASX Share Market News & Research
  1. Home
  2. Companies
  3. NGEN
Healthcare
Facebook Twitter Linkedin

NervGen Pharma Corp (TSXV:NGEN)

2.42 CAD

-0.020 0.820%
Last Updated at: 2024-10-04T19:52:00Z

NervGen Pharma Corp

NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company's lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.

2955 Virtual Way, Vancouver, BC, Canada, V5M 4X6

778 731 1711

https://www.nervgen.com

Key Executives

Sr. No. Name Title Year Born
1. Mr. William Joseph Radvak BASc Co-Founder, Interim CEO & Exec. Chairman 1963
2. Dr. Harold Martin Punnett D.M.D. Co-Founder & Independent Director NA
3. Mr. William J. Adams C.A., CPA, CA, CPA CFO & Corp. Sec. 1962
4. Dr. Daniel D. Mikol M.D., Ph.D. Chief Medical Officer NA
5. Dr. Adam H. Rogers M.D. Interim Pres & Director NA
6. Mr. Brian McAlister Co-Founder & Advisor NA

Peers

Sector: Healthcare

Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE(x) Forward PE(x) Price Sales TTM(x) Price to Book Value(x) Enterprise Value to Revenue(x) Enterprise Value to EBITDA(x)
ARCH

Arch Biopartners Inc

 +0.030 1.639% 1.85 0.000 0.000 37.823 0.000 53.055 -28.103
MIR

MedMira Inc

 0.000 0.000% 0.09 0.000 0.000 170.457 0.000 189.937 -48.737
TTI

Thiogenesis Therapeutics Corp.

 0.000 0.000% 0.67 0.000 0.000 0.000 11.863 0.000 -163.079
SBM

Sirona Biochem Corp

 0.000 0.000% 0.08 0.000 0.000 343.735 41.637 359.744 -13.882

Income Statement

(Currency in CAD)
Breakdown 31-12-2022 31-12-2021 31-12-2020 31-12-2019 31-12-2018
Income Before Tax -20.722M -12.727M -11.186M -9.766M -1.358M
Minority Interest - - - - -
Net Income -20.722M -12.727M -11.186M -9.766M -1.358M
Selling General Administrative 6.338M 4.504M 5.031M 3.379M 0.578M
Gross Profit - - - - -
Reconciled Depreciation 0.115M 0.043M 0.04M 0.038M 0.02M
Ebit -23.025M -12.811M -11.196M -9.864M -1.358M
Ebitda -20.093M -11.335M -11.156M -9.826M -1.339M
Depreciation And Amortization - - - - -
Operating Income -23.025M -11.377M -11.196M -9.864M -1.358M
Other Operating Expenses - - - - -
Interest Expense 0.515M 0M 0M 0M 0M
Tax Provision - - - - -
Interest Income 0.201M 0.029M 0.019M 0.099M -
Net Interest Income -0.313M -1.404M 0.019M 0.099M -
Income Tax Expense - - - - -
Total Revenue 0M 0M 0M 0M 0M
Total Operating Expenses 23.025M 11.377M 11.196M 9.864M 1.358M
Cost Of Revenue - - - - -
Total Other Income Expense Net 2.616M 0.055M -0.009M - -
Net Income From Continuing Ops -20.722M -12.727M -11.186M -9.766M -1.358M
Net Income Applicable To Common Shares -20.722M -12.727M -11.186M -9.766M -1.358M

Balance Sheet

(Currency in CAD)
Breakdown 31-12-2022 31-12-2021 31-12-2020 31-12-2019 31-12-2018
Total Assets 23.875M 17.896M 6.675M 6.765M 3.097M
Intangible Assets 0.431M 0.473M 0.471M 0.51M 0.548M
Other Current Assets 0.59M 0.363M 0.492M 1.984M -
Total Liab 10.414M 1.078M 0.755M 0.924M 0.583M
Total Stockholder Equity 13.461M 16.818M 5.92M 5.842M 2.514M
Other Current Liab 6.732M 0.274M 0.163M - 0.134M
Common Stock 57.412M 42.403M 22.947M 15.294M 3.847M
Capital Stock 57.412M 42.403M 22.947M 15.294M 3.847M
Retained Earnings -55.771M -35.049M -22.322M -11.136M -1.37M
Good Will - - - - -
Other Assets - - - - -
Cash 22.452M 16.929M 5.599M 4.106M 2.474M
Cash And Equivalents - - - - -
Total Current Liabilities 10.217M 1.078M 0.755M 0.924M 0.449M
Current Deferred Revenue - - - - -
Net Debt - - - - -
Short Term Debt - - - - -
Short Long Term Debt - - - - -
Short Long Term Debt Total - - - - -
Other Stockholder Equity 11.82M 9.464M 5.295M 1.684M 0.038M
Property Plant Equipment 0.295M 0.003M 0.002M - -
Total Current Assets 23.149M 17.42M 6.202M 6.256M 2.55M
Long Term Investments - - - - -
Short Term Investments - - - - -
Net Receivables 0.027M 0.064M 0.063M 0.123M 0.026M
Long Term Debt - - - - -
Inventory - - - - -
Accounts Payable 2.002M 0.353M 0.172M 0.502M 0.046M
Accumulated Other Comprehensive Income - - - - -
Non Currrent Assets Other - - - 0.51M 0.548M
Non Current Assets Total 0.727M 0.476M 0.473M 0.51M 0.548M
Capital Lease Obligations 0.283M - - - -
Long Term Debt Total - - - - -

Cash Flow

(Currency in CAD)
Breakdown 31-12-2022 31-12-2021 31-12-2020 31-12-2019 31-12-2018
Investments -0.021M -0.045M -0.003M 0M -0.127M
Total Cashflows From Investing Activities -0.021M -0.045M -0.003M -0.003M -0.127M
Total Cash From Financing Activities 22.641M 19.613M 7.849M 9.839M 3.591M
Net Income -20.722M -12.727M -11.186M -9.766M -1.358M
Change In Cash 5.523M 11.33M 1.502M 1.632M 2.474M
Begin Period Cash Flow 16.929M 5.599M 4.106M 2.474M 0M
End Period Cash Flow 22.452M 16.929M 5.599M 4.106M 2.474M
Total Cash From Operating Activities -17.784M -8.269M -6.298M -8.094M -1.04M
Depreciation 0.115M 0.043M 0.04M 0.038M 0.02M
Other Cashflows From Investing Activities - - - - -
Dividends Paid - - - - -
Change To Inventory - - - - -
Sale Purchase Of Stock - - - - -
Other Cashflows From Financing Activities -0.129M -1.666M -1.169M -0.901M -0.901M
Capital Expenditures 0.021M 0.003M 0.003M 0.003M 0.003M
Change In Working Capital 2.115M 0.43M 1.408M 0.207M 0.304M
Other Non Cash Items 0.529M - - - -
Free Cash Flow -17.805M -8.314M -6.31M -8.094M -1.167M

No data found

Disclaimer

Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

Related Articles

Code Price Chg %Chg
View All
Code Price Chg %Chg
View All
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Open in the App